Correll CU, Davis RE, Weingart M, et al. - Researchers sought to explore the utility and safety of lumateperone for the short-term treatment of schizophrenia. They conducted a randomized, double-blind, placebo-controlled, phase 3 clinical trial involving a sum of 450 patients (mean [SD] age, 42.4 [10.2] years; 346 [77.1%] male; mean [SD] baseline PANSS score, 89.8 [10.3]; mean [SD] baseline CGI-S score, 4.8 [0.6]) between November 13, 2014 and July 20, 2015, with data analyses performed from August 13 to September 15, 2015. They found that 42 mg of lumateperone indicated statistically significant differences in decreasing symptoms of schizophrenia without treatment-emergent motor, cardiometabolic, or endocrine adverse effects compared with placebo. For treatment of schizophrenia, lumateperone is a potential and has a favorable safety profile.